The total return over the past 12 months is +116.73% vs. +16.94% for the S&P 500. So far it's up +105.31% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +116.73% | +1.23% | (13.40%) | (8.51%) | +9.12% | +1.62% |
| Total Return CAGR | +116.73% | +1.23% | (13.40%) | (8.51%) | +9.12% | +1.62% |
| Revenue CAGR | +31.36% | (9.37%) | (2.48%) | +1.55% | +5.19% | +7.16% |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | (39.38%) | (26.88%) | (13.08%) | (10.66%) |
| Operating Cash Flow CAGR | (4.81%) | N/A | (10.34%) | (15.13%) | (1.08%) | (1.23%) |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Anika Therapeutics, Inc. (ANIK)
| Year | Start price | End price | ANIK Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $9.61 | $19.73 | +105.31% | +14.51% | +90.80% |
| 2025 | $16.46 | $9.61 | (41.62%) | +17.72% | (59.34%) |
| 2024 | $22.66 | $16.46 | (27.36%) | +24.89% | (52.25%) |
| 2023 | $29.60 | $22.66 | (23.45%) | +26.19% | (49.64%) |
| 2022 | $35.83 | $29.60 | (17.39%) | (18.17%) | +0.78% |
| 2021 | $45.26 | $35.83 | (20.84%) | +28.74% | (49.58%) |
| 2020 | $51.85 | $45.26 | (12.71%) | +18.37% | (31.08%) |
| 2019 | $33.61 | $51.85 | +54.27% | +31.22% | +23.05% |
| 2018 | $53.91 | $33.61 | (37.66%) | (4.56%) | (33.10%) |
| 2017 | $48.96 | $53.91 | +10.11% | +21.70% | (11.59%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
